Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Name: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Published: 2017
License: Public Domain

Melanoma Institute Australia · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

biomarkers immune-response melanoma pembrolizumab

melanoma, neoadjuvant therapy, pembrolizumab, dabrafenib, trametinib, pathological response, recist, immune response, braf, randomised, stage iiib/c, biomarkers, tumour

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 880753
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.